丨2026年7月28日星期二丨 NO.1 石药创新:预计上半年盈利11.8亿元~13.6亿元,同比扭亏 石药创新披露业绩预告,预计2026年上半年归母净利润11.8亿元~13.6亿元,同比扭亏为盈,上年同期亏损274.61万元。报告期内,公司生物制药业务研发成果持续兑现。控股子公司巨石生物与阿斯利康签署《战略合作与授权协议》,将与阿斯利康在创新多肽分子药物领域开展合作。巨石生物已于5月29日...
Source Link丨2026年7月28日星期二丨 NO.1 石药创新:预计上半年盈利11.8亿元~13.6亿元,同比扭亏 石药创新披露业绩预告,预计2026年上半年归母净利润11.8亿元~13.6亿元,同比扭亏为盈,上年同期亏损274.61万元。报告期内,公司生物制药业务研发成果持续兑现。控股子公司巨石生物与阿斯利康签署《战略合作与授权协议》,将与阿斯利康在创新多肽分子药物领域开展合作。巨石生物已于5月29日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.